Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. is strategically advancing its OST-HER2 program towards potential accelerated approval, having successfully completed a Type C meeting with the FDA, which has clarified the path for a Biologics License Application (BLA) filing for metastatic osteosarcoma. Additionally, the company achieved critical regulatory alignment with the UK Medicines and Healthcare products Regulatory Agency (MHRA), marking a significant milestone in the journey towards conditional approval in the UK. The ongoing efforts to leverage immune-response biomarker data as a efficacy endpoint in clinical trials further enhance the outlook for OST-HER2, positioning the company favorably for future clinical and regulatory successes.

Bears say

OS Therapies Inc. faces significant challenges due to the inherent complexities associated with osteosarcoma, as evidenced by its poor responsiveness to receptor-level HER2 inhibition and antibody therapies. Furthermore, the disease's immunologically "cold" and genetically unstable nature poses a considerable hurdle for the development and commercialization of effective treatments. These factors collectively contribute to a concerning outlook regarding the company's ability to achieve sustainable growth and market success in a competitive biopharmaceutical landscape.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.